# Alumis Inc.: financial statements, quarterly

ALMS · Nasdaq · CIK 1847367 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alms.md) · [Financials](/companies/alms/financials.md) · [Filings](/companies/alms/filings.md) · [Insiders](/companies/alms/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alms/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [17.4](/filings/0001847367-26-000010.md) | [2.7](/filings/0001847367-26-000018.md) | [2.1](/filings/0001847367-25-000050.md) | [1.9 d](/filings/0001847367-26-000006.md) | [1.7](/filings/0001847367-26-000010.md) | [1.7](/filings/0001847367-26-000018.md) |
| Research and development | $m | [37.8](/filings/0001847367-24-000005.md) | [34.6 d](/filings/0001847367-25-000012.md) | [42.0](/filings/0001847367-25-000028.md) | [48.6](/filings/0001847367-25-000041.md) | [87.8](/filings/0001847367-25-000050.md) | [87.2 d](/filings/0001847367-26-000006.md) | [96.6](/filings/0001847367-26-000010.md) | [109](/filings/0001847367-26-000018.md) | [97.8](/filings/0001847367-25-000050.md) | [82.8 d](/filings/0001847367-26-000006.md) | [81.5](/filings/0001847367-26-000010.md) | [85.3](/filings/0001847367-26-000018.md) |
| Operating income | $m | [(43.8)](/filings/0001847367-24-000005.md) | [(40.1) d](/filings/0001847367-25-000012.md) | [(47.6)](/filings/0001847367-25-000028.md) | [(56.1)](/filings/0001847367-25-000041.md) | [(98.4)](/filings/0001847367-25-000050.md) | [(98.6) d](/filings/0001847367-26-000006.md) | [(102)](/filings/0001847367-26-000010.md) | [(141)](/filings/0001847367-26-000018.md) | [(115)](/filings/0001847367-25-000050.md) | [(96.4) d](/filings/0001847367-26-000006.md) | [(98.4)](/filings/0001847367-26-000010.md) | [(149)](/filings/0001847367-26-000018.md) |
| Income tax | $m | not reported | not reported | not reported | [0.0](/filings/0001847367-25-000041.md) | [0.0](/filings/0001847367-25-000050.md) | [0.0 d](/filings/0001847367-26-000006.md) | not reported | [(8.6)](/filings/0001847367-26-000018.md) | [0.0](/filings/0001847367-25-000050.md) | [0.0 d](/filings/0001847367-26-000006.md) | not reported | [(1.8)](/filings/0001847367-26-000018.md) |
| Net income | $m | [(43.4)](/filings/0001847367-24-000005.md) | [(39.3) d](/filings/0001847367-25-000012.md) | [(49.8)](/filings/0001847367-25-000050.md) | [(56.5)](/filings/0001847367-25-000050.md) | [(93.1)](/filings/0001847367-25-000050.md) | [(94.8) d](/filings/0001847367-26-000006.md) | [(99.0)](/filings/0001847367-26-000018.md) | [59.3](/filings/0001847367-26-000018.md) | [(111)](/filings/0001847367-25-000050.md) | [(92.9) d](/filings/0001847367-26-000006.md) | [(93.1)](/filings/0001847367-26-000018.md) | [(142)](/filings/0001847367-26-000018.md) |
| Diluted EPS | $ per share | [(19.76)](/filings/0001847367-24-000005.md) | not reported | [(21.03)](/filings/0001847367-25-000028.md) | [(23.10)](/filings/0001847367-25-000041.md) | [(1.73)](/filings/0001847367-25-000050.md) | not reported | [(1.82)](/filings/0001847367-26-000010.md) | [0.77](/filings/0001847367-26-000018.md) | [(1.06)](/filings/0001847367-25-000050.md) | not reported | [(0.74)](/filings/0001847367-26-000010.md) | [(1.11)](/filings/0001847367-26-000018.md) |
| Basic EPS | $ per share | [(19.76)](/filings/0001847367-24-000005.md) | not reported | [(21.03)](/filings/0001847367-25-000028.md) | [(23.10)](/filings/0001847367-25-000041.md) | [(1.73)](/filings/0001847367-25-000050.md) | not reported | [(1.82)](/filings/0001847367-26-000010.md) | [0.78](/filings/0001847367-26-000018.md) | [(1.06)](/filings/0001847367-25-000050.md) | not reported | [(0.74)](/filings/0001847367-26-000010.md) | [(1.11)](/filings/0001847367-26-000018.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [53.9](/filings/0001847367-24-000005.md) | [46.0](/filings/0001847367-25-000012.md) | [112](/filings/0001847367-25-000028.md) | [155](/filings/0001847367-25-000041.md) | [213](/filings/0001847367-25-000050.md) | [170](/filings/0001847367-26-000006.md) | [129](/filings/0001847367-26-000010.md) | [152](/filings/0001847367-26-000018.md) | [65.3](/filings/0001847367-25-000050.md) | [89.7](/filings/0001847367-26-000018.md) | [63.9](/filings/0001847367-26-000010.md) | [63.7](/filings/0001847367-26-000018.md) |
| Current assets | $m | not reported | [53.4](/filings/0001847367-25-000012.md) | not reported | [225](/filings/0001558370-24-012081.md) | [377](/filings/0001847367-24-000005.md) | [306](/filings/0001847367-26-000006.md) | [226](/filings/0001847367-25-000028.md) | [518](/filings/0001847367-25-000041.md) | [393](/filings/0001847367-25-000050.md) | [318](/filings/0001847367-26-000018.md) | [532](/filings/0001847367-26-000010.md) | [514](/filings/0001847367-26-000018.md) |
| Total assets | $m | not reported | [89.6](/filings/0001847367-25-000012.md) | not reported | [265](/filings/0001558370-24-012081.md) | [413](/filings/0001847367-24-000005.md) | [341](/filings/0001847367-26-000006.md) | [261](/filings/0001847367-25-000028.md) | [611](/filings/0001847367-25-000041.md) | [488](/filings/0001847367-25-000050.md) | [412](/filings/0001847367-26-000018.md) | [672](/filings/0001847367-26-000010.md) | [561](/filings/0001847367-26-000018.md) |
| Current liabilities | $m | not reported | [20.9](/filings/0001847367-25-000012.md) | not reported | [33.4](/filings/0001558370-24-012081.md) | [33.5](/filings/0001847367-24-000005.md) | [50.9](/filings/0001847367-26-000006.md) | [60.5](/filings/0001847367-25-000028.md) | [85.6](/filings/0001847367-25-000041.md) | [65.4](/filings/0001847367-25-000050.md) | [73.3](/filings/0001847367-26-000018.md) | [70.9](/filings/0001847367-26-000010.md) | [76.2](/filings/0001847367-26-000018.md) |
| Total liabilities | $m | not reported | [53.5](/filings/0001847367-25-000012.md) | not reported | [64.7](/filings/0001558370-24-012081.md) | [64.2](/filings/0001847367-24-000005.md) | [80.9](/filings/0001847367-26-000006.md) | [93.0](/filings/0001847367-25-000028.md) | [126](/filings/0001847367-25-000041.md) | [103](/filings/0001847367-25-000050.md) | [111](/filings/0001847367-26-000018.md) | [105](/filings/0001847367-26-000010.md) | [108](/filings/0001847367-26-000018.md) |
| Shareholders' equity | $m | [(303)](/filings/0001847367-24-000005.md) | [(339)](/filings/0001847367-26-000006.md) | [(386)](/filings/0001847367-25-000050.md) | [(439)](/filings/0001847367-25-000050.md) | [348](/filings/0001847367-25-000050.md) | [260](/filings/0001847367-26-000018.md) | [168](/filings/0001847367-26-000018.md) | [485](/filings/0001847367-26-000018.md) | [385](/filings/0001847367-25-000050.md) | [301](/filings/0001847367-26-000018.md) | [567](/filings/0001847367-26-000018.md) | [452](/filings/0001847367-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(33.2) d](/filings/0001847367-24-000005.md) | [(33.7) d](/filings/0001847367-25-000012.md) | [(44.3)](/filings/0001847367-25-000028.md) | [(52.3) d](/filings/0001847367-25-000041.md) | [(83.8) d](/filings/0001847367-25-000050.md) | [(74.8) d](/filings/0001847367-26-000006.md) | [(80.4)](/filings/0001847367-26-000010.md) | [(106) d](/filings/0001847367-26-000018.md) | [(111) d](/filings/0001847367-25-000050.md) | [(71.9) d](/filings/0001847367-26-000006.md) | [(87.1)](/filings/0001847367-26-000010.md) | [(81.5) d](/filings/0001847367-26-000018.md) |
| Capital expenditure | $m | [2.2 d](/filings/0001847367-24-000005.md) | [1.2 d](/filings/0001847367-25-000012.md) | [0.2](/filings/0001847367-25-000028.md) | [0.4 d](/filings/0001847367-25-000041.md) | [0.8 d](/filings/0001847367-25-000050.md) | [0.4 d](/filings/0001847367-26-000006.md) | [0.0](/filings/0001847367-26-000010.md) | [0.6 d](/filings/0001847367-26-000018.md) | [0.0 d](/filings/0001847367-25-000050.md) | [0.0 d](/filings/0001847367-26-000006.md) | [0.2](/filings/0001847367-26-000010.md) | [0.2 d](/filings/0001847367-26-000018.md) |
| Share repurchases | $m | [0.0 d](/filings/0001847367-24-000005.md) | [0.0 d](/filings/0001847367-25-000012.md) | not reported | not reported | not reported | [0.0 d](/filings/0001847367-26-000006.md) | not reported | not reported | [0.0 d](/filings/0001847367-25-000050.md) | [0.0 d](/filings/0001847367-26-000006.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.1](/filings/0001558370-24-012081.md) | [2.2](/filings/0001847367-24-000005.md) | [2.4](/filings/0001847367-25-000028.md) | [2.4](/filings/0001847367-25-000041.md) | [53.8](/filings/0001847367-25-000050.md) | [65.4](/filings/0001847367-26-000018.md) | [76.6](/filings/0001847367-26-000018.md) | [104](/filings/0001847367-25-000050.md) | [125](/filings/0001847367-26-000010.md) | [128](/filings/0001847367-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.